Partner with AgriViro
One platform. Three ways to partner.
AgriViro’s integrated campus — its R&D Discovery Platform, industrial Production Platform, and regulatory-validated biologicals portfolio — is open to a range of strategic commercial partnerships. Whether you are seeking African market entry, production capacity, or a first-mover supply agreement, we have structured models designed for each.
For Companies Seeking African Market Entry
Proven pathway into African market without local infrastructure cost
AgriViro offers international agrochemical and AgBio companies — including traditional players transitioning into biologicals and biorationals — a proven pathway into the African market, without the capital cost of building local infrastructure, conducting local field trials, or navigating African regulatory processes from scratch.
What we bring to a multinational partnership:
- Regulatory-ready biologicals with field validation across African agro-climatic zones
- Industrial-scale production capacity for biologicals and biorationals
- In-country regulatory expertise and established relationships
- A platform that supports licensing, co-development, and contract production
- First-mover positioning in a rapidly expanding market
For Regional Distributors
First-mover advantage with regulatory-ready, proven product range
AgriViro’s biologicals portfolio is entering the market. We are seeking established regional distributors who want a first-mover advantage with a regulatory-ready, proven product range. What a distribution partnership offers:
- Regulatory-approved biologicals ahead of broader market availability
- Multi-site African field validation data to present to customers
- Biorational classification — marketable to growers and export markets with sustainability requirements
- A supply partner with on-site production capacity and quality control
- A genuinely differentiated range in a market still dominated by synthetic chemistries
For Investors
If you are evaluating AgriViro as an investment opportunity, please visit our Investor Relations page for the full investment context — platform overview, commercialisation stage, and partnership models.